Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Integra Lifesciences Affirms FY2025 Adj EPS Guidance of $2.19-$2.29 vs $2.24 Est; Narrows FY2025 Sales Guidance from $1.650B-$1.715B to $1.655B-$1.680B vs $1.667B Est

Author: Benzinga Newsdesk | July 31, 2025 05:08am
Integra Lifesciences (NASDAQ:IART) affirms FY2025 Adj EPS guidance from $2.19-$2.29 to $2.19-$2.29 vs $2.24 analyst estimate. Narrows FY2025 sales outlook from $1.650 billion-$1.715 billion to $1.655 billion-$1.680 billion vs $1.667 billion estimate.

Posted In: IART


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist